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Background: Vitamin D deficiency (VDD) is inversely associated with insulin resistance. We studied the prevalence
of VDD across the spectrum of glucose intolerance, including normal glucose tolerance (NGT), prediabetes (PD) and
type 2 diabetes (T2D).
Methods: We conducted this cross-sectional, observational study by serially including the PD and T2D patients seen
between June and December 2014. We excluded patients with major illness, secondary diabetes and use of vitamin D
or glucocorticoids. VDD was defined as serum 25-hydroxy vitamin D (25OHD) less than 30 ng/mL. The study population
was divided into 3 groups: T2D (Group 1; n = 274), PD (Group 2; n = 62) and NGT controls (Group 3; n = 270) for the
analysis and appropriate statistical methods were used.
Results: The study participants (n = 606, 28 % males) had a mean age of 43.2 ± 13.6 years, BMI of 27.7 ± 5.9 kg/m2,
HbA1c of 6.6 ± 2 % and mean 25OHD of 18.8 ± 15.7 ng/mL. VDD was seen in 85 % of the entire study
population including 84 % in T2D, 77 % in prediabetes and in 87 % of the controls. The mean 25OHD levels
were lower in the control group (16.8 ng/mL) when compared with T2D and prediabetes (19.9 and 22.4 ng/mL)
respectively (P = 0.0124). Univariate analysis showed higher odds of VDD in females (P < 0.0001) but no association with
diabetes, age, BMI and HbA1c.
Conclusion: Our data showed that VDD is prevalent in the majority of the population, irrespective of the
underlying glucose intolerance. Further studies are required to determine the association between the vitamin D
and diabetes.
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Vitamin D deficiency (VDD) is the most widely reported
nutritive deficiency leading to increased concern amongst
the general public and medical fraternity [1]. The skeletal
role of vitamin D was established in the last century and
vitamin D therapy leads to a marked reduction in the
prevalence of rickets and osteomalacia [2]. Researchers
have identified the presence of vitamin D receptors in
many extra skeletal tissues, giving an expanded role for
vitamin D. The extensive actions of vitamin D prompted
few investigators to label the compound as a hormone in-
stead of vitamin [3]. This deficiency has been implicated
as a risk factor in many autoimmune, metabolic and neo-
plastic disorders during the last decade [4]. Observational* Correspondence: hariendo@rediffmail.com
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a myriad of metabolic abnormalities, including hyperten-
sion, diabetes, dyslipidemia and obesity [5]. Previous re-
ports suggest the presence of VDD in more than 90 % of
Indians and the neighboring Asian countries, whereas it
falls to about 40 % in patients from the developed coun-
tries [6].
The role of vitamin D has been established in the
carbohydrate metabolism, insulin secretion and its intra-
cellular action [7]. During the last decade, there is an ex-
ponential rise in the research pertaining to vitamin D in
glucose intolerance. Epidemiological studies suggest a
higher risk of type 2 diabetes (T2D) in patients with
VDD and studies are exploring the therapeutic role of
vitamin D in the management of diabetes [8]. T2D and
prediabetes (PD) are a major public health problem in
India with a population prevalence of 13 % together [9].icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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proximate conversion rate of 5 % annually [10]. The
prevalence of VDD has not been studied across the
spectrum of diabetes in India and very few reports exist
from other developed countries [11]. Hence, we con-
ducted this study to assess the prevalence of VDD in pa-
tients with PD and T2D.
Methods
Study population
This was a cross-sectional, observational study conducted
at two tertiary level hospitals located in south India (lati-
tude: 170 37′) and north India (latitude: 300 74′). The par-
ticipants were recruited from the outpatient department
of the hospital. Serial patients with a diagnosis of T2D and
PD, aged between 18 and 65 years seen between June
2014 and December 2014 were included in the study. We
excluded patients with any major illness (end stage kidney
disease, cirrhosis, pancreatitis, cancer and cardiovascular
disorders), recent surgery or diabetic ketoacidosis in last
6 months, use of glucocorticoids or vitamin D and second-
ary diabetes. Control population was derived from the pa-
tients attending the obesity and thyroid clinic with normal
glucose tolerance (NGT) and are free from any systemic ill-
ness. We included equal number of controls to the T2D pa-
tients (within 5 % variation to minimise the statistical error
in final analysis) and all the control population had normal
thyroid and glucose profile on biochemical measurements.
The patients were divided into 3 groups for the analysis
as per the underlying diagnosis: Group 1 (T2D; n = 274),
Group 2 (PD; n = 62) and Group 3 (NGT; n = 270).
Study measures
Clinical data and demographic details like age, sex, fam-
ily history of diabetes and duration of diabetes were ob-
tained from all the participants through personal
interview method. The study population hails from dif-
ferent regions of our country with varying dietary pat-
terns. Hence, we did not include the dietary patterns
influencing the vitamin D in the study questionnaire.
Weight was recorded on a digital weighing scale using
OMRON HN 286 (Omron Corporation, Kyoto, Japan
with a sensitivity of 100 g), height by using a SWWS05
stadiometer (Multicare Company, Delhi, India with a
sensitivity of 0.1 cm) and body mass index (BMI) was
calculated as weight in kilograms divided height in me-
ters squared [12]. The blood pressure was checked by
using an OMRON-HEM 7120 electronic instrument
over right arm in the sitting position, and three readings
were taken at one minute intervals. The average of all
three measures was taken for the study purpose. Fasting
venous blood samples were collected after an overnight
fast for more than 8 h and analyzed for glucose, glycosyl-
ated hemoglobin (HbA1c) and 25-hydroxy vitamin D(25OHD). Post meal blood sample for glucose was col-
lected 2 h after meal consumption. Plasma glucose was
estimated by the glucose oxidase method, HbA1c was esti-
mated by high pressure liquid chromatography method
and 25OHD by the chemiluminescence method. The coef-
ficients of variation for HbA1c, glucose, and 25OHD were
8, 10, and 7.5 %, respectively at our laboratory. The local
ethics committee (Independent Review Board, Dr Modi's
Clinic and Institutional Ethical Committee, Command
Hospital) approved the study protocol at both the centres
and all patients provided written informed consent. We
followed the international ethical guidelines issued by the
World Health Organization to conduct this study [13].
Definitions
Glucose intolerance is defined as the presence of either
prediabetes (impaired fasting glucose or impaired glu-
cose tolerance) or T2D. We used the American Diabetes
Association (ADA) recommendations for the diagnosis
of prediabetes and T2D [14]. Endocrine society clinical
practice guidelines define vitamin D deficiency as levels of
25OHD < 20 ng/mL, vitamin D insufficiency as 25OHD
between 21 and 29 ng/mL and normal status as 25OHD
level more than 30 ng/mL [15]. In our study, we consid-
ered any value including and above 30 ng/mL as normal
and less than 30 ng/mL as deficiency for the sake of clarity
and analysis. All the participants with hypovitaminosis D
were given oral replacement of vitamin D after collection
of the blood sample.
Statistical analysis
Data are presented as mean, standard deviation (SD)
and descriptive statistics were used for the data analysis.
Sprearman’s correlation and Kruskal-Wallis test (post
hoc analysis with Bonferroni method) was used to com-
pare between the data between the groups. We used the
nonparametric methods for comparison because the
sample was derived from a specialized group attending
the hospital and not derived from the population. To
identify the associations with vitamin D, univariate logistic
regression analysis was conducted with vitamin D defi-
ciency (Yes/No) as a dependent variable and others as in-
dependent continuous variables. The results are expressed
as odds ratio (OR) and 95 % confidence intervals (CI). A
two-tailed p value of less than 0.05 was considered signifi-
cant for all the tests. The statistical analysis and graph
generation was done using the Graph Pad Prism Software,
Version 6 (Graph Pad Software, San Deigo, CA, USA).
Results
The study participants (n = 606, 28 % males) had a mean
age of 43.2 ± 13.6 years, BMI of 27.7 ± 5.9 kg/m2, HbA1c
of 6.6 ± 2 % and mean 25OHD of 18.8 ± 15.7 ng/mL.
VDD was seen in 84 % of T2D, 77 % of prediabetes and
Fig. 1 Odds ratio of the study parameters with vitamin D deficiency
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sample only 90 out of 606 (15 %) patients had normal
vitamin D levels. The baseline parameters and detailed
comparison between the three groups are given in
Table 1. The mean 25OHD levels were lower in the con-
trol group when compared with T2D and prediabetes
(16.8, 19.9, 22.4 ng/mL, P = 0.0124) patients. Briefly, the
results show that the patients with glycemic intolerance
were older and females were in the majority in all the
three groups. Systolic and diastolic blood pressures were
higher in the diabetes population and the BMI was com-
parable between the three groups. Post hoc analysis re-
vealed that 25OHD was significantly less in Group 3
compared to Group 1 and the same was significantly
lower than the Group 2. The analysis also showed a sig-
nificant difference between Groups 1 and 2 pertaining to
all the study parameters except for the blood pressure,
BMI and 25OHD values.
Logistic regression models were used to quantify the as-
sociation between vitamin D levels and the presence of
diabetes. The presence of VDD did not differ with the
diagnosis of diabetes (OR: 1.4673, CI: 0.9241 – 2.3298),
age (OR: 0.7316, CI: 0.4589 – 1.1663), BMI (OR: 1.3641,
CI: 0.8648 – 2.1518) and HbA1c (OR: 0.9797, CI: 0.6235 –
1.5394). In view of the lack of association between VDD
and diagnosis of diabetes, we did not perform the multi-
variate analysis. Female sex had higher odds of having a
vitamin D deficiency (OR: 6.6132, CI: 4.0922 – 10.6871,
P < 0.0001) as shown in Fig. 1. Spearman’s test did not
show any correlation between vitamin D level and the
age, duration of diabetes and HbA1c (Data not shown).
Discussion
Our study showed that only 15 % of the study population
have normal 25OHD levels. The interesting observation ofTable 1 Demographic and biochemical parameters in the three stu
Feature Unit Group 1
(T2D)
n = 274
Age years 50 ± 11.6
Gender M/F 102/172
Duration of disease years 5.9 ± 3.4
Body Mass Index kg/m2 27.8 ± 5.8
Systolic BP mm Hg 124.1 ± 15.2
Diastolic BP mm Hg 79.3 ± 9.2
Fasting glucose mg/dl 166.7 ± 65.5
Post meal glucose mg/dl 243.5 ± 93.3
HbA1c % 8.4 ± 1.6
25-OH Vitamin D ng/ml 19.9 ± 18.3
Mean (SD)
*months
Significant values are highlighted in boldour study is the higher levels of 25OHD in the glycemic
intolerance group than the control population. Similar
finding was observed in a recently published report from
the neighboring Asian country [11]. Patients with T2D
and prediabetes are more exposed to the mass media cam-
paigns, public health awareness programs and also consult
the physician frequently for the primary diagnosis [16, 17].
Nevertheless, this could have led to their conscious efforts
by increasing the dietary intake of vitamin D coupled with
adequate sun exposure to achieve a higher 25OHD level.
Population studies from India showed a prevalence of
vitamin D in more than 90 % of the patients [18]. Previous
reports from other Asian nations also reported VDD in
more than 80 % of their population [6, 19]. Our results
also suggest that a majority (85 %) of the study population
have vitamin D deficiency irrespective of the underlying
glycemic status.
Other finding of our study is a markedly higher preva-
lence of VDD in female sex (Fig. 1). The majority of our
clientele hails from Muslim community and their cul-
tural etiquette requires wearing a long robe calleddy groups
Group 2 Group 3 P value
(Prediabetes) (Controls)
n = 62 n = 270
42.8 ± 12.8 36.3 ± 12.2 <0.0001
15/47 52/218 <0.0001
*6.1 ± 3.6 - -
28.5 ± 7.7 27.4 ± 5.6 0.3982
123.5 ± 11.7 116.9 ± 9.1 <0.0001
78.4 ± 9.3 73.4 ± 8.1 <0.0001
103.6 ± 10.8 81.6 ± 11.2 <0.0001
140.2 ± 27.3 118.9 ± 11.4 <0.0001
5.9 ± 0.26 4.9 ± 0.45 <0.0001
22.4 ± 18.6 16.8 ± 11.5 0.0124
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clothes covers the skin completely preventing the synthesis
of vitamin D in the skin [20]. The unique factors respon-
sible for the high prevalence of VDD in our country include
dark skin, lack of sunlight exposure, poor dietary consump-
tion and lack of food fortification [21]. The identification of
VDD as a modifiable risk factor for skeletal and metabolic
disorders prompted the developing countries to fortify the
food substances and milk with vitamin D [22].
Multiple mechanisms link the presence of VDD with gly-
cemic intolerance. They include reduction in the calcium
mediated insulin secretion, decreased expression of the in-
sulin receptors, increase in the oxidative stress and inflam-
matory cytokines and low adiponectin levels [4]. Our study
showed a trend of higher odds of glycemic intolerance in
patients with vitamin D deficiency. However, it was not sta-
tistically significant and 25OHD status showed no associ-
ation with age, obesity and HbA1c. Recent reports suggest
that vitamin D is a modifiable risk factor for the obesity
and the obesity inducing effects of the FTO gene (name de-
rived from the Fused Toes and Other abnormalities ob-
served in the mice with the specific gene deletion) were
observed more in patients with VDD [23, 24]. However, our
data did not show any association between the BMI and
VDD (OR: 1.3641, CI: 0.8648 – 2.1518). The strength of
our study lies in the inclusion of patients from north and
south India giving a pan Indian representation, and the
findings may be extrapolated to the entire country. The
limitations include small sample size, inability to nullify the
confounding factors and the cross sectional design of the
study. Prospective studies with large number of patients in-
cluding a representative Indian sample are required to
study the link between vitamin D deficiency and other fac-
tors related to the diabetes mellitus.
Conclusion
To conclude, our data showed a high prevalence of
VDD in the sample irrespective of the glycemic status.
Our study gives more impetus to researchers and policy
makers to improve vitamin D status of the population by
public education about sun exposure and food fortifica-
tion to reduce the morbidity associated with VDD.
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